The survival benefit associated with high-dose IL-2 in metastatic renal cell carcinoma may be better than previously believed.
A large, multicenter study “definitively demonstrates” the treatment’s infectiveness, one expert says.
The study shows a wide discrepancy between the least and most expensive ways to treat the common prostate condition.
Research on the quality of bladder biopsy and bladder cancer survival point to problems of suboptimal biopsies and incorrect tumor staging, researchers say.
Atlanta—Patients who undergo radical prostatectomy for clinical stage T4 prostate cancer have a higher survival rate than do patients who receive radiation or hormone therapies alone, and surgical prostate cancer patients' survival is comparable to that of patients who receive both hormone and radiation therapies.
Orlando, FL—In the throes of the PSA era, with stage migration and improved therapies, the impact of family history on prostate cancer prognosis has become minimal, according to a new study.
Ann Arbor, MI—Evidence-based expectant management of men with lower-risk prostate cancer does not seem to be catching on among physicians and their patients. A new study suggests that, among men who are appropriate candidates for the wait-and-see approach, physicians are treating more than half with surgery or radiation therapy.